» Articles » PMID: 26225839

Integrated Genomic Analyses Identify KDM1A's Role in Cell Proliferation Via Modulating E2F Signaling Activity and Associate with Poor Clinical Outcome in Oral Cancer

Overview
Journal Cancer Lett
Specialty Oncology
Date 2015 Jul 31
PMID 26225839
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The histone demethylase KDM1A specifically demethylates lysine residues and its deregulation has been implicated in the initiation and progression of various cancers. However, KDM1A's molecular role and its pathological consequences, and prognostic significance in oral cancer remain less understood. In the present study, we sought to investigate the expression of KDM1A and its downstream role in oral cancer pathogenesis. By comparing mRNA expression profiles, we identified an elevated KDM1A expression in oral tumors when compared to normal oral tissues. In silico pathway prediction identified the association between KDM1A and E2F1 signaling in oral cancer. Pathway scanning, functional annotation analysis and In vitro assays showed the KDM1A's involvement in oral cancer cell proliferation and the cell cycle. Moreover, real time PCR and luciferase assays confirmed KDM1A's role in regulation of E2F1 signaling activity in oral cancer. Elevated KDM1A expression is associated with poor clinical outcome in oral cancer. Our data indicate that deregulated KDM1A expression is positively associated with proliferative phenotype of oral cancer and confers poor clinical outcome. These cumulative data suggest that KDM1A might be a potential diagnostic and therapeutic target for oral cancer.

Citing Articles

Advances in the study of posttranslational modifications of histones in head and neck squamous cell carcinoma.

Xiao Y, Zhang Y, Hu Y, Zhang X, Tan J, Yao S Clin Epigenetics. 2024; 16(1):165.

PMID: 39574168 PMC: 11580233. DOI: 10.1186/s13148-024-01785-w.


MAPKAPK2-centric transcriptome profiling reveals its major role in governing molecular crosstalk of IGFBP2, MUC4, and PRKAR2B during HNSCC pathogenesis.

Soni S, Anand P, Swarnkar M, Patial V, Tirpude N, Padwad Y Comput Struct Biotechnol J. 2023; 21:1292-1311.

PMID: 36817960 PMC: 9929207. DOI: 10.1016/j.csbj.2023.01.039.


The Emerging Significance of Histone Lysine Demethylases as Prognostic Markers and Therapeutic Targets in Head and Neck Cancers.

Dorna D, Paluszczak J Cells. 2022; 11(6).

PMID: 35326475 PMC: 8946939. DOI: 10.3390/cells11061023.


Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression.

Agboyibor C, Dong J, Effah C, Drokow E, Pervaiz W, Li D Cancer Control. 2021; 28:10732748211051557.

PMID: 34802287 PMC: 8727833. DOI: 10.1177/10732748211051557.


Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.

Punnia-Moorthy G, Hersey P, Al Emran A, Tiffen J Front Genet. 2021; 12:680633.

PMID: 34220955 PMC: 8242339. DOI: 10.3389/fgene.2021.680633.


References
1.
Berger S . Histone modifications in transcriptional regulation. Curr Opin Genet Dev. 2002; 12(2):142-8. DOI: 10.1016/s0959-437x(02)00279-4. View

2.
Ding J, Zhang Z, Xia Y, Liao G, Pan Y, Liu S . LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br J Cancer. 2013; 109(4):994-1003. PMC: 3749561. DOI: 10.1038/bjc.2013.364. View

3.
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

4.
Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

5.
Pajtler K, Weingarten C, Thor T, Kunkele A, Heukamp L, Buttner R . The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. Acta Neuropathol Commun. 2013; 1:19. PMC: 3893444. DOI: 10.1186/2051-5960-1-19. View